OrbiMed Advisors
http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.
View Older Stories View More Recent Stories
-
Form SC 13G Ophthotech Corp. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A InspireMD, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A NEUROCRINE BIOSCIENCES Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G MAGELLAN HEALTH INC Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Mirati Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A MEI Pharma, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A MOLINA HEALTHCARE INC Filed by: ORBIMED ADVISORS LLC
-
Adimab Provides Update on Recent Partnerships and Milestones
-
NextCure, Inc., New Immuno-Oncology Firm, Announces $67 Million Series A Financing
-
OrbiMed Advisors Sells Nearly 500K Shares of RELYPSA (RLYP); Still Has Significant 17.75% Stake
-
Form SC 13D/A Relypsa Inc Filed by: ORBIMED ADVISORS LLC
-
Form 4 Relypsa Inc For: Dec 21 Filed by: ORBIMED ADVISORS LLC
-
Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act
-
Viralytics Completes $28 million Placement -- SPP to Follow
-
Form 4 Otonomy, Inc. For: Nov 25 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Otonomy, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Loxo Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
-
Neurostimulation Established as a Treatment Option for Sleep Apnea Patients Who Do Not Tolerate CPAP
-
Conference Forum's Immuno-Oncology 360° Announces the Support of Key Partnerships to Present Multiple Views to Advance IO as a Standard of Cancer Treatment
-
Form SC 13D/A Adaptimmune Therapeutics Filed by: ORBIMED ADVISORS LLC
-
Form 13F-HR ORBIMED ADVISORS LLC For: Sep 30
-
Xtant Medical Holdings, Inc. Reports Third Quarter 2015 Results
-
Inspire Medical Systems to Present at Three Upcoming Investor Conferences
-
Form SC 13D Dimension Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Relypsa Inc Filed by: ORBIMED ADVISORS LLC
-
Healthbox Returns to Israel to Accelerate Entrepreneurs' Access to the US Market
-
EY and SolomonEdwards honor the 2015 Venture Capital Award of Excellence winners
-
The Galien Foundation Announces Partnership with Business France to Foster US-France Life Sciences Innovation via MedStartUp Program
-
Form 4 Sientra, Inc. For: Oct 12 Filed by: ORBIMED ADVISORS LLC
-
Form 4 Sientra, Inc. For: Oct 07 Filed by: ORBIMED ADVISORS LLC
-
Form 4 Sientra, Inc. For: Oct 02 Filed by: ORBIMED ADVISORS LLC
-
Onxeo Announces Evolution in the Board of Directors
-
TytoCare Hires Jeff Cutler to Lead Commercial Launch of its Remote Home Exam Platform
-
Form SC 13D Nabriva Therapeutics AG Filed by: ORBIMED ADVISORS LLC
-
Form 4 Sientra, Inc. For: Sep 29 Filed by: ORBIMED ADVISORS LLC
-
U.S. biotech bloodbath hits hedge funds but some bargains emerge
-
Biotech stocks sink after Hillary Clinton 'price gouging' tweet
-
ContraFect Appoints Key Business Executives
-
Form SC 13G/A Biotie Therapies Corp. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Affimed N.V. Filed by: ORBIMED ADVISORS LLC
-
Form 13F-HR ORBIMED ADVISORS LLC For: Jun 30
-
Xtant Medical Reports First Half 2015 Financial Results
-
Xtant Medical Reports First Half 2015 Financial Results
-
Avitide, Inc., Secures Series C Financing to Expand On-demand Biopharmaceutical Affinity Purification Platform and Achieve Profitability
-
Form SC 13D PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
-
Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics
-
Form SC 13G Cynapsus Therapeutics Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Biotie Therapies Corp. Filed by: ORBIMED ADVISORS LLC
-
Clementia Pharmaceuticals Raises U.S. $60 Million in Mezzanine Financing to Support Development of Palovarotene for Fibrodysplasia Ossificans Progressiva

